Chan Julie Y H, Wang Ling-Lin, Chao Yung-Mei, Chan Samuel H H
Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, Republic of China.
Hypertension. 2003 Mar;41(3):563-70. doi: 10.1161/01.HYP.0000054214.10670.4C. Epub 2003 Feb 10.
We demonstrated recently that a significant reduction in both the molecular synthesis and functional expression of inducible nitric oxide synthase (iNOS) in the rostral ventrolateral medulla (RVLM), the medullary origin of sympathetic vasomotor outflow, underlies the augmented sympathetic vasomotor tone during hypertension. This study further evaluated the hypothesis that this downregulation of basal iNOS at the RVLM during hypertension is innate. In adult spontaneously hypertensive rats (SHR) treated for 4 weeks with the antihypertensive captopril to normalize elevated blood pressure or in young prehypertensive SHR, the significantly lower iNOS mRNA and protein levels at the ventrolateral medulla under basal conditions or on activation by microinjection bilaterally into the RVLM of lipopolysaccharide (10 ng) remained unaltered. The retarded efficacy of lipopolysaccharide (10 ng) to elicit cardiovascular depression (hypotension, bradycardia, and reduction in sympathetic vasomotor tone) also persevered in captopril-treated adult or young normotensive SHR. On the other hand, compared with Wistar-Kyoto normotensive rats, the magnitude of cardiovascular depression induced in adult SHR by local administration into the RVLM of the NO precursor l-arginine (40 nmol) was significantly smaller. In addition, microinjection bilaterally into the RVLM of a selective iNOS inhibitor, aminoguanidine (125 or 250 pmol), was discernibly less efficacious in unmasking hypertension, tachycardia, and the increase in sympathetic vasomotor tone in adult SHR. We conclude that a predisposed reduction in molecular synthesis and functional expression of basal iNOS in the RVLM is associated with the sympathetic vasomotor overactivity during hypertension.
我们最近证明,延髓头端腹外侧区(RVLM)是交感缩血管神经传出纤维的起源部位,高血压期间诱导型一氧化氮合酶(iNOS)的分子合成和功能表达显著降低,是交感缩血管紧张增强的基础。本研究进一步评估了高血压期间RVLM处基础iNOS下调是先天性的这一假说。用降压药卡托普利治疗4周以使血压升高正常化的成年自发性高血压大鼠(SHR)或年轻的高血压前期SHR,基础条件下或双侧向RVLM微量注射脂多糖(10 ng)激活后,腹外侧髓质中iNOS mRNA和蛋白水平显著降低的情况未发生改变。脂多糖(10 ng)引发心血管抑制(低血压、心动过缓和交感缩血管紧张降低)的作用减弱,在卡托普利治疗的成年或年轻血压正常的SHR中也持续存在。另一方面,与Wistar-Kyoto正常血压大鼠相比,成年SHR经向RVLM局部注射NO前体L-精氨酸(40 nmol)诱导的心血管抑制程度明显较小。此外,双侧向成年SHR的RVLM微量注射选择性iNOS抑制剂氨基胍(125或250 pmol),在揭示高血压、心动过速和交感缩血管紧张增加方面的效果明显较差。我们得出结论,RVLM中基础iNOS的分子合成和功能表达预先降低与高血压期间交感缩血管活动过度有关。